As­traZeneca gains EU nod for di­a­betes triple; Am­gen and Duke launch re­al-world PC­SK9 ob­ser­va­tion­al study

→ Weeks af­ter win­ning EU ap­proval to start mar­ket­ing da­pagliflozin as Forx­i­ga, As­traZeneca has racked up an­oth­er OK for a triplet com­bo in­volv­ing the SGLT2 di­a­betes drug. Named Qtril­met, the pill com­bines Forx­i­ga with the DPP-4 in­hibitor Ong­lyza (saxagliptin) and the bedrock drug met­formin in a mod­i­fied-re­lease for­mat. That 3-in-1 ap­proach proved su­pe­ri­or in re­duc­ing av­er­age blood glu­cose lev­els to a num­ber of oth­er dual com­bi­na­tions across 5 Phase III tri­als, in­clud­ing Forx­i­ga plus met­formin, Ong­lyza with met­formin, or glimepiri­de with met­formin.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.